查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1968594

被忽视的热带疾病治疗市场分析及预测（至2035年）：按类型、产品类型、服务、技术、应用、格式、实施类型、最终用户、解决方案和交付类型划分

Neglected Tropical Disease Treatment Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Form, Deployment, End User, Solutions, Mode
出版日期: | 出版商: Global Insight Services | 英文 443 Pages | 商品交期: 3-5个工作天内

价格
简介目录

被忽视的热带疾病治疗市场预计将从2024年的46.4亿美元成长到2034年的72.4亿美元，复合年增长率约为4.5%。该市场涵盖针对热带地区流行且在贫困地区普遍存在的疾病的治疗方法和干预措施。市场内容包括利什曼原虫症、利甚曼病和南美锥虫病等疾病的药物、疫苗和病媒控制解决方案。全球医疗保健倡议和资金的不断增加正在推动治疗和创新的可近性提升，从而兼顾预防和根除工作，同时强调在服务不足的地区提供永续的医疗保健解决方案。

在公众意识不断提高和医疗解决方案不断进步的推动下，被忽视的热带疾病治疗市场持续发展。其中，药品领域成长最为迅猛，抗寄生虫药物因其在治疗多种疾病的有效性而占据主导。疫苗已成为一个极具发展潜力的细分领域，随着研究的深入，展现出巨大的成长潜力。诊断工具，尤其是快速诊断测试，是成长速度第二快的领域。它们能够快速且准确地检测疾病，这在资源匮乏的环境中至关重要。创新的药物输送系统也推动了市场的动态，提高了治疗顺从性和疗效。公私合营发挥关键作用，促进了研发倡议。对生物技术和基因组研究的投资有望推动未来的进步，并为新型治疗方法铺平道路。人们越来越关注永续的医疗解决方案，尤其註重可负担性和可近性，以满足全球服务不足人口的需求。

市场区隔
类型 抗寄生虫药、抗菌药、抗病毒药及抗真菌药物
产品 药品、疫苗、诊断试剂和治疗设备
服务 临床试验、咨询、监管服务和分销服务
科技 生物技术、奈米技术、基因体学、蛋白质体学
应用领域 人类健康、兽医学、研究和公共卫生倡议
剂型 片剂、胶囊、注射剂、外用製剂
安装位置 医院药局、零售药局、网路药局、实验室
最终用户 医院、诊所、研究机构、政府机构、非营利组织
解决方案 疾病管理、病患监测、数据分析、供应链管理
提供的表格 线下、远程、混合式

市场概况：

被忽视的热带疾病治疗市场正经历市场份额、定价和产品创新方面的动态变化。老牌製药公司和新兴生技公司都在积极推出新的治疗方法，加剧了市场竞争。在低收入地区对可负担解决方案的需求推动下，定价策略也不断演变。该市场的特点是治疗方案多样化，涵盖传统疗法和创新治疗方法。这种情况造就了竞争激烈的市场环境，各公司都在寻求透过策略联盟和合作来扩大市场占有率。市场竞争异常激烈，主要参与者都试图透过对竞争对手进行比较评估来获得优势。监管的影响至关重要，严格的指导方针规范产品开发和核准流程。旨在支持研发的全球卫生倡议和国际组织的资金也对市场产生影响。在应对监管环境的同时，各公司也致力于扩大治疗的可及性，尤其是在服务不足的地区。创新与策略性监管合规的结合有望推动市场成长。

主要趋势和驱动因素：

由于公众意识的提高和政府主导的倡议，被忽视的热带疾病治疗市场正在成长。主要趋势包括研发投入的增加，这推动了治疗方法的创新。製药公司正在加强与非政府组织的合作，以提高治疗的可及性和可负担性。对疫苗研发的重视也促进了市场扩张。该市场的主要驱动因素包括发展中地区被忽视的热带疾病日益普遍，从而刺激了对有效治疗方法的需求。国际卫生组织增加的资金支持了新治疗方法的研发，而公私合营在加速药物研发过程中发挥关键作用。此外，生物技术领域的技术进步提高了药物发现和开发的效率。新兴经济体医疗基础设施的扩展，透过改善治疗方法的分配和可近性，创造了新的机会。专注于成本效益高且扩充性解决方案的公司更有可能获得市场份额。此外，对预防保健和早期疗育的日益重视将推动对诊断工具和疫苗的需求，从而确保市场的持续成长。

限制与挑战：

被忽视的热带疾病治疗市场面临许多限制和挑战。其中一项主要挑战是资金短缺，这阻碍了研发工作。资金不足限制了创新治疗方法的应用，并阻碍了市场扩张。此外，受影响地区缺乏训练有素的医护人员也影响了治疗的实施和疗效。同时，资源匮乏地区疾病诊断的复杂性也为及时且准确的治疗带来了重大障碍。监管壁垒和冗长的核准流程延缓了新疗法的推广，进一步限制了市场成长。最后，贫穷和教育匮乏等社会经济因素加剧了病患取得和坚持治疗计画的困难。所有这些挑战迭加在一起，限制了该市场满足被忽视的热带疾病患者需求的潜力。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 抗寄生虫药物
    • 抗菌剂
    • 抗病毒药物
    • 抗真菌剂
  • 市场规模及预测：依产品划分
    • 药物
    • 疫苗
    • 诊断试剂
    • 治疗设备
  • 市场规模及预测：依服务划分
    • 临床试验
    • 咨询
    • 监管服务
    • 分销服务
  • 市场规模及预测：依技术划分
    • 生物技术
    • 奈米科技
    • 基因组学
    • 蛋白质体学
  • 市场规模及预测：依应用领域划分
    • 人类健康
    • 兽医学
    • 调查
    • 公共卫生措施
  • 市场规模及预测：依类型
    • 药片
    • 胶囊
    • 注射
    • 外用药物
  • 市场规模及预测：依发展状况
    • 医院药房
    • 零售药房
    • 网路药房
    • 研究所
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊所
    • 研究所
    • 政府机构
    • 非营利组织
  • 市场规模及预测：按解决方案划分
    • 疾病管理
    • 病患监测
    • 数据分析
    • 供应链管理
  • 市场规模及预测：按模式
    • 面对面
    • 偏僻的
    • 杂交种

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Eisai Co Ltd
  • Sanofi Pasteur
  • Gilead Sciences
  • Boehringer Ingelheim
  • Fujifilm Holdings Corporation
  • Merck KGaA
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc
  • GlaxoSmithKline plc
  • AbbVie Inc
  • Bayer AG
  • Roche Holding AG
  • AstraZeneca
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Takeda Pharmaceutical Company
  • Amgen Inc
  • Biocon Limited
  • Cipla Limited

第九章：关于我们

简介目录
Product Code: GIS33174

Neglected Tropical Disease Treatment Market is anticipated to expand from $4.64 billion in 2024 to $7.24 billion by 2034, growing at a CAGR of approximately 4.5%. The Neglected Tropical Disease Treatment Market encompasses therapies and interventions targeting diseases prevalent in tropical regions, often affecting impoverished communities. This market includes pharmaceuticals, vaccines, and vector control solutions aimed at diseases such as dengue, leishmaniasis, and Chagas disease. Increasing global health initiatives and funding are driving advancements in treatment accessibility and innovation, addressing both prevention and eradication efforts, while emphasizing sustainable healthcare solutions in underserved regions.

The Neglected Tropical Disease Treatment Market is evolving, driven by increased awareness and advancements in healthcare solutions. The pharmaceutical segment is the top-performing sector, with antiparasitic drugs leading due to their efficacy in treating a range of diseases. Vaccines are emerging as a promising sub-segment, showing potential for significant growth as research progresses. Diagnostic tools, particularly rapid diagnostic tests, are gaining traction as the second-highest performing segment. They offer quick and accurate disease detection, crucial in resource-limited settings. Innovative drug delivery systems are also contributing to market dynamics, enhancing treatment adherence and efficacy. The role of public-private partnerships is pivotal, fostering research and development initiatives. Investments in biotechnology and genomic research are expected to drive future advancements, paving the way for novel therapeutics. The focus on sustainable healthcare solutions is increasing, with an emphasis on affordability and accessibility, addressing the needs of underserved populations worldwide.

Market Segmentation
TypeAntiparasitic, Antibacterial, Antiviral, Antifungal
ProductDrugs, Vaccines, Diagnostics, Therapeutic Devices
ServicesClinical Trials, Consulting, Regulatory Services, Distribution Services
TechnologyBiotechnology, Nanotechnology, Genomics, Proteomics
ApplicationHuman Health, Veterinary, Research, Public Health Initiatives
FormTablets, Capsules, Injectables, Topicals
DeploymentHospital Pharmacies, Retail Pharmacies, Online Pharmacies, Research Laboratories
End UserHospitals, Clinics, Research Institutes, Government Organizations, Non-Profit Organizations
SolutionsDisease Management, Patient Monitoring, Data Analytics, Supply Chain Management
ModeIn-Person, Remote, Hybrid

Market Snapshot:

The Neglected Tropical Disease Treatment Market is experiencing dynamic shifts in market share, pricing, and product innovation. Established pharmaceutical companies and emerging biotech firms are actively launching new treatments, driving competition. Pricing strategies are evolving, influenced by the need for affordable solutions in low-income regions. The market is characterized by a diverse range of therapeutic products, with a focus on both traditional and novel treatment modalities. This landscape is fostering a competitive environment where companies are striving to enhance their market presence through strategic partnerships and collaborations. Competition within the market is intense, with key players benchmarking their offerings against rivals to gain a competitive edge. Regulatory influences play a crucial role, with stringent guidelines shaping product development and approval processes. The market is influenced by global health initiatives and funding from international organizations, which support research and development efforts. As companies navigate regulatory landscapes, they are also focusing on expanding access to treatment, particularly in underserved regions. The market is poised for growth, driven by a combination of innovation and strategic regulatory compliance.

Geographical Overview:

The Neglected Tropical Disease (NTD) Treatment Market is witnessing varied growth across different regions, each showcasing unique opportunities. Africa remains a focal point, driven by high disease prevalence and increased governmental and non-governmental interventions. Countries like Nigeria and the Democratic Republic of the Congo are emerging as key players due to extensive healthcare initiatives. In Asia Pacific, India and Indonesia are notable for their robust public health campaigns and expanding pharmaceutical sectors, which are critical in addressing NTDs. The region's economic growth and healthcare investments are propelling market expansion. Latin America, led by Brazil and Mexico, is experiencing growth through increased awareness and public health policies aimed at combating NTDs. The Middle East shows potential, particularly in countries like Saudi Arabia, where healthcare modernization is a priority. These regions present lucrative opportunities for stakeholders aiming to invest in innovative treatments and infrastructure to tackle NTDs effectively.

Key Trends and Drivers:

The Neglected Tropical Disease Treatment Market is experiencing growth due to increased awareness and governmental initiatives. Key trends include the rising investment in research and development, which is fostering innovation in treatment options. Pharmaceutical companies are collaborating with non-governmental organizations to enhance accessibility and affordability of treatments. There is also a growing emphasis on developing vaccines, contributing to the market's expansion. Drivers for this market include the rising prevalence of neglected tropical diseases in developing regions, prompting a demand for effective treatments. Increased funding from international health organizations is supporting the development of new therapies. Public-private partnerships are playing a crucial role in accelerating drug development processes. Furthermore, technological advancements in biotechnology are enabling more efficient drug discovery and development. Opportunities are emerging in the form of expanding healthcare infrastructure in emerging economies, which is enhancing the distribution and accessibility of treatments. Companies focusing on cost-effective and scalable solutions are well-positioned to capture market share. Additionally, the increasing focus on preventive care and early intervention is likely to drive demand for diagnostic tools and vaccines, ensuring sustained market growth.

Restraints and Challenges:

The neglected tropical disease treatment market encounters significant restraints and challenges. A primary challenge is inadequate funding, which hampers research and development efforts. This financial shortfall limits the availability of innovative treatments and hinders market expansion. Additionally, there is a scarcity of skilled healthcare professionals in affected regions, which affects the delivery and effectiveness of treatments. Furthermore, the complexity of disease diagnosis in resource-limited settings poses a significant barrier to timely and accurate treatment. Regulatory hurdles and lengthy approval processes delay the introduction of new therapies, further constraining market growth. Lastly, socio-economic factors, such as poverty and lack of education, exacerbate the difficulty in accessing and adhering to treatment regimens. These challenges collectively impede the market's potential to address the needs of those suffering from neglected tropical diseases.

Key Players:

Eisai Co Ltd, Sanofi Pasteur, Gilead Sciences, Boehringer Ingelheim, Fujifilm Holdings Corporation, Merck KGaA, Johnson & Johnson, Novartis AG, Pfizer Inc, GlaxoSmithKline plc, AbbVie Inc, Bayer AG, Roche Holding AG, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Takeda Pharmaceutical Company, Amgen Inc, Biocon Limited, Cipla Limited

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Form
  • 2.7 Key Market Highlights by Deployment
  • 2.8 Key Market Highlights by End User
  • 2.9 Key Market Highlights by Solutions
  • 2.10 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Antiparasitic
    • 4.1.2 Antibacterial
    • 4.1.3 Antiviral
    • 4.1.4 Antifungal
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Drugs
    • 4.2.2 Vaccines
    • 4.2.3 Diagnostics
    • 4.2.4 Therapeutic Devices
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Clinical Trials
    • 4.3.2 Consulting
    • 4.3.3 Regulatory Services
    • 4.3.4 Distribution Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Biotechnology
    • 4.4.2 Nanotechnology
    • 4.4.3 Genomics
    • 4.4.4 Proteomics
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Human Health
    • 4.5.2 Veterinary
    • 4.5.3 Research
    • 4.5.4 Public Health Initiatives
  • 4.6 Market Size & Forecast by Form (2020-2035)
    • 4.6.1 Tablets
    • 4.6.2 Capsules
    • 4.6.3 Injectables
    • 4.6.4 Topicals
  • 4.7 Market Size & Forecast by Deployment (2020-2035)
    • 4.7.1 Hospital Pharmacies
    • 4.7.2 Retail Pharmacies
    • 4.7.3 Online Pharmacies
    • 4.7.4 Research Laboratories
  • 4.8 Market Size & Forecast by End User (2020-2035)
    • 4.8.1 Hospitals
    • 4.8.2 Clinics
    • 4.8.3 Research Institutes
    • 4.8.4 Government Organizations
    • 4.8.5 Non-Profit Organizations
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Disease Management
    • 4.9.2 Patient Monitoring
    • 4.9.3 Data Analytics
    • 4.9.4 Supply Chain Management
  • 4.10 Market Size & Forecast by Mode (2020-2035)
    • 4.10.1 In-Person
    • 4.10.2 Remote
    • 4.10.3 Hybrid

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 Form
      • 5.2.1.7 Deployment
      • 5.2.1.8 End User
      • 5.2.1.9 Solutions
      • 5.2.1.10 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 Form
      • 5.2.2.7 Deployment
      • 5.2.2.8 End User
      • 5.2.2.9 Solutions
      • 5.2.2.10 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 Form
      • 5.2.3.7 Deployment
      • 5.2.3.8 End User
      • 5.2.3.9 Solutions
      • 5.2.3.10 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 Form
      • 5.3.1.7 Deployment
      • 5.3.1.8 End User
      • 5.3.1.9 Solutions
      • 5.3.1.10 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 Form
      • 5.3.2.7 Deployment
      • 5.3.2.8 End User
      • 5.3.2.9 Solutions
      • 5.3.2.10 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 Form
      • 5.3.3.7 Deployment
      • 5.3.3.8 End User
      • 5.3.3.9 Solutions
      • 5.3.3.10 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 Form
      • 5.4.1.7 Deployment
      • 5.4.1.8 End User
      • 5.4.1.9 Solutions
      • 5.4.1.10 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 Form
      • 5.4.2.7 Deployment
      • 5.4.2.8 End User
      • 5.4.2.9 Solutions
      • 5.4.2.10 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 Form
      • 5.4.3.7 Deployment
      • 5.4.3.8 End User
      • 5.4.3.9 Solutions
      • 5.4.3.10 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 Form
      • 5.4.4.7 Deployment
      • 5.4.4.8 End User
      • 5.4.4.9 Solutions
      • 5.4.4.10 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 Form
      • 5.4.5.7 Deployment
      • 5.4.5.8 End User
      • 5.4.5.9 Solutions
      • 5.4.5.10 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 Form
      • 5.4.6.7 Deployment
      • 5.4.6.8 End User
      • 5.4.6.9 Solutions
      • 5.4.6.10 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 Form
      • 5.4.7.7 Deployment
      • 5.4.7.8 End User
      • 5.4.7.9 Solutions
      • 5.4.7.10 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 Form
      • 5.5.1.7 Deployment
      • 5.5.1.8 End User
      • 5.5.1.9 Solutions
      • 5.5.1.10 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 Form
      • 5.5.2.7 Deployment
      • 5.5.2.8 End User
      • 5.5.2.9 Solutions
      • 5.5.2.10 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 Form
      • 5.5.3.7 Deployment
      • 5.5.3.8 End User
      • 5.5.3.9 Solutions
      • 5.5.3.10 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 Form
      • 5.5.4.7 Deployment
      • 5.5.4.8 End User
      • 5.5.4.9 Solutions
      • 5.5.4.10 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 Form
      • 5.5.5.7 Deployment
      • 5.5.5.8 End User
      • 5.5.5.9 Solutions
      • 5.5.5.10 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 Form
      • 5.5.6.7 Deployment
      • 5.5.6.8 End User
      • 5.5.6.9 Solutions
      • 5.5.6.10 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 Form
      • 5.6.1.7 Deployment
      • 5.6.1.8 End User
      • 5.6.1.9 Solutions
      • 5.6.1.10 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 Form
      • 5.6.2.7 Deployment
      • 5.6.2.8 End User
      • 5.6.2.9 Solutions
      • 5.6.2.10 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 Form
      • 5.6.3.7 Deployment
      • 5.6.3.8 End User
      • 5.6.3.9 Solutions
      • 5.6.3.10 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 Form
      • 5.6.4.7 Deployment
      • 5.6.4.8 End User
      • 5.6.4.9 Solutions
      • 5.6.4.10 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 Form
      • 5.6.5.7 Deployment
      • 5.6.5.8 End User
      • 5.6.5.9 Solutions
      • 5.6.5.10 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Eisai Co Ltd
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Sanofi Pasteur
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Gilead Sciences
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Boehringer Ingelheim
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Fujifilm Holdings Corporation
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Merck KGaA
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Johnson & Johnson
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Novartis AG
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Pfizer Inc
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 GlaxoSmithKline plc
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 AbbVie Inc
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Bayer AG
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Roche Holding AG
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 AstraZeneca
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Bristol-Myers Squibb
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Eli Lilly and Company
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Takeda Pharmaceutical Company
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Amgen Inc
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Biocon Limited
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Cipla Limited
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us